These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9500784)

  • 21. Defining a novel domain of staphylococcal toxic shock syndrome toxin-1 critical for major histocompatibility complex class II binding, superantigenic activity, and lethality.
    Kum WW; Laupland KB; Chow AW
    Can J Microbiol; 2000 Feb; 46(2):171-9. PubMed ID: 10721486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distinct binding sites on HLA-DR for invariant chain and staphylococcal enterotoxins.
    Karp DR; Jenkins RN; Long EO
    Proc Natl Acad Sci U S A; 1992 Oct; 89(20):9657-61. PubMed ID: 1409679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutational analysis of the binding of staphylococcal enterotoxin D to the T cell receptor Vbeta chain and major histocompatibility complex class II.
    Li Y; Zhu X; Huang Y; Xiong H
    Immunol Lett; 2006 May; 105(1):55-60. PubMed ID: 16481046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TCR binding differs for a bacterial superantigen (SEE) and a viral superantigen (Mtv-9).
    Liao L; Marinescu A; Molano A; Ciurli C; Sekaly RP; Fraser JD; Popowicz A; Posnett DN
    J Exp Med; 1996 Oct; 184(4):1471-82. PubMed ID: 8879218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Localization of a site on bacterial superantigens that determines T cell receptor beta chain specificity.
    Mollick JA; McMasters RL; Grossman D; Rich RR
    J Exp Med; 1993 Feb; 177(2):283-93. PubMed ID: 7678849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Binding of toxic shock syndrome toxin-1 to murine major histocompatibility complex class II molecules.
    Scholl PR; Sekaly RP; Diez A; Glimcher LH; Geha RS
    Eur J Immunol; 1990 Sep; 20(9):1911-6. PubMed ID: 2209697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Major histocompatibility complex class II-associated peptides determine the binding of the superantigen toxic shock syndrome toxin-1.
    von Bonin A; Ehrlich S; Malcherek G; Fleischer B
    Eur J Immunol; 1995 Oct; 25(10):2894-8. PubMed ID: 7589089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Crystal structure of a T-cell receptor beta-chain complexed with a superantigen.
    Fields BA; Malchiodi EL; Li H; Ysern X; Stauffacher CV; Schlievert PM; Karjalainen K; Mariuzza RA
    Nature; 1996 Nov; 384(6605):188-92. PubMed ID: 8906797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Superantigen natural affinity maturation revealed by the crystal structure of staphylococcal enterotoxin G and its binding to T-cell receptor Vbeta8.2.
    Fernández MM; Bhattacharya S; De Marzi MC; Brown PH; Kerzic M; Schuck P; Mariuzza RA; Malchiodi EL
    Proteins; 2007 Jul; 68(1):389-402. PubMed ID: 17427250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequences in both class II major histocompatibility complex alpha and beta chains contribute to the binding of the superantigen toxic shock syndrome toxin 1.
    Braunstein NS; Weber DA; Wang XC; Long EO; Karp D
    J Exp Med; 1992 May; 175(5):1301-5. PubMed ID: 1569399
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Superantigen binding to a T cell receptor beta chain of known three-dimensional structure.
    Malchiodi EL; Eisenstein E; Fields BA; Ohlendorf DH; Schlievert PM; Karjalainen K; Mariuzza RA
    J Exp Med; 1995 Dec; 182(6):1833-45. PubMed ID: 7500029
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enterotoxin residues determining T-cell receptor V beta binding specificity.
    Irwin MJ; Hudson KR; Fraser JD; Gascoigne NR
    Nature; 1992 Oct; 359(6398):841-3. PubMed ID: 1436060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human scFvs That Counteract Bioactivities of Staphylococcus aureus TSST-1.
    Rukkawattanakul T; Sookrung N; Seesuay W; Onlamoon N; Diraphat P; Chaicumpa W; Indrawattana N
    Toxins (Basel); 2017 Feb; 9(2):. PubMed ID: 28218671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The structural basis of T cell activation by superantigens.
    Li H; Llera A; Malchiodi EL; Mariuzza RA
    Annu Rev Immunol; 1999; 17():435-66. PubMed ID: 10358765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD1d-independent activation of mouse and human iNKT cells by bacterial superantigens.
    Hayworth JL; Mazzuca DM; Maleki Vareki S; Welch I; McCormick JK; Haeryfar SM
    Immunol Cell Biol; 2012 Aug; 90(7):699-709. PubMed ID: 22041925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interference of distinct invariant chain regions with superantigen contact area and antigenic peptide binding groove of HLA-DR.
    Vogt AB; Stern LJ; Amshoff C; Dobberstein B; Hämmerling GJ; Kropshofer H
    J Immunol; 1995 Nov; 155(10):4757-65. PubMed ID: 7594477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biological properties of staphylococcal enterotoxin-like toxin type R.
    Omoe K; Imanishi K; Hu DL; Kato H; Takahashi-Omoe H; Nakane A; Uchiyama T; Shinagawa K
    Infect Immun; 2004 Jun; 72(6):3664-7. PubMed ID: 15155681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T cell receptor interaction with peptide/major histocompatibility complex (MHC) and superantigen/MHC ligands is dominated by antigen.
    Ehrich EW; Devaux B; Rock EP; Jorgensen JL; Davis MM; Chien YH
    J Exp Med; 1993 Aug; 178(2):713-22. PubMed ID: 8393480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HLA-DO increases bacterial superantigen binding to human MHC molecules by inhibiting dissociation of class II-associated invariant chain peptides.
    Pezeshki AM; Azar GA; Mourad W; Routy JP; Boulassel MR; Denzin LK; Thibodeau J
    Hum Immunol; 2013 Oct; 74(10):1280-7. PubMed ID: 23756162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Superantigen and class II MHC molecules.
    Kim J
    J Korean Med Sci; 1995 Dec; 10(6):393-8. PubMed ID: 8924222
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.